Therapeutic process for the treatment of the pathologies of Type II diabetes

A method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human subject which comprises

• administering to said subject a prolactin-inhibiting compound once a day, at a predetermined time within a 24-hour period, in an amount sufficient, and for a period of time sufficient to accomplish at least one of the following:
• decrease insulin resistance, decrease hyperglycemia, decrease hyperinsulinemia in said subject, and increase glucose tolerance.

A method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human subject comprising

• administering to said subject a prolactin-inhibiting compound on a timed daily basis at a time of day designed to cause the daytime prolactin bloodstream level of said subject to decrease at a time corresponding to the low daytime prolactin level of a lean, insulin sensitive subject, in a dosage amount sufficient and for a period of time sufficient to achieve in said subject at least one of the following modifications in glucose metabolism:
• decrease in insulin resistance, reduction of hyperinsulinemia, improvement in glucose tolerance and reduction of hyperglycemia.

A method for modifying or regulating the glucose metabolism of a human subject exhibiting at least one of the pathologies characteristically associated with Type II diabetes comprising

• administering a prolactin-inhibiting compound on a timed daily basis from about 1 hour to about 10 hours after the time at which the prolactin bloodstream level peaks in a member of the same species and sex as said subject, wherein said member is not exhibiting any of said pathologies associated with Type II diabetes, in a dosage amount within the range from about 3 micrograms to about 100 micrograms per pound body weight of said subject, and for a period of time sufficient to achieve in said subject at least one of the following modifications in glucose metabolism:
• decrease in insulin resistance, reduction of hyperinsulinemia, reduction of hyperglycemia.

A method for modifying and resetting the neural phase oscillations of the brain which control bloodstream prolactin levels of a human subject, said subject being diagnosed as being at least one of insulin insensitive and diabetic, said method comprising

• administering to said subject a prolactin-inhibiting compound once a day, at an hour, in an amount, and for a period of time sufficient to decrease insulin insensitivity and decrease hyperglycemia in said subject.

A method for modifying and regulating lipid metabolism in an animal or human subject in need of such treatment comprising

• administering to said subject a prolactin-inhibiting compound on a timed basis in a dosage amount and for a period of time sufficient to achieve in said subject either a decrease in body fat stores or an increase in body fat stores.